By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Matinas BioPharma 

915 Klosterman Road East

Tarpon Springs  Florida  34689  U.S.A.
Phone: 1-908-443-1860 Fax: n/a


Company News
Matinas BioPharma Announces Trading On NYSE MKT To Commence March 2, 2017 2/27/2017 7:53:01 AM
Matinas BioPharma Release: Company Provides Business Outlook And Sets Corporate Milestones For 2017 1/26/2017 7:39:01 AM
Matinas BioPharma Release: Company Successfully Completes Warrant Tender Offer – Raises $13.5 Million From Exercise Of Warrants 1/19/2017 7:09:29 AM
Matinas BioPharma Receives Contract Award From Cystic Fibrosis Foundation Therapeutics, Inc. To Study MAT2501 For The Treatment Of NTM-Infection In Pre-Clinical Models Of CF 12/8/2016 7:29:40 AM
Matinas BioPharma Commences Dosing In Phase I Study Of Orally Administered Aminoglycoside Antibiotic MAT2501 12/5/2016 8:36:27 AM
Matinas BioPharma Initiates Enrollment And Commences Patient Dosing In Phase II Study Of MAT2203 For The Treatment Of Vulvovaginal Candidiasis 11/21/2016 10:40:23 AM
Matinas BioPharma Reports 2016 Third Quarter Financial Results And Provides Corporate Update 11/15/2016 9:22:44 AM
Matinas BioPharma Receives Notice Of Allowance Of U.S. Patent For Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology 10/24/2016 8:36:53 AM
Matinas BioPharma To Present At The 2nd Annual Dawson James Securities Growth Stock Conference 10/13/2016 8:50:11 AM
Matinas BioPharma Commences Patient Dosing In NIH-Sponsored Phase IIa Study With Lead Anti-Infective Candidate MAT2203 9/28/2016 7:43:19 AM